The saga continues for Orexigen Therapeutics Inc. now that the Ninth Circuit has opened the door for an amended shareholders' complaint alleging securities fraud stemming from SEC filings and statements company officials made about interim study results for obesity drug Contrave (naltrexone and bupropion).